16:15 , Apr 5, 2019 |  BC Week In Review  |  Company News

Sandoz resubmits BLA for Neulasta biosimilar

Sandoz said it resubmitted a BLA to FDA for LA-EP2006 to treat neutropenia in patients with non-myeloid malignancies receiving myelosuppressive drugs. LA-EP2006 is a biosimilar of Neulasta pegfilgrastim from Amgen Inc. (NASDAQ:AMGN). The resubmission from...